Mitotane Associated With Cisplatin, Etoposide, and Doxorubicin in Advanced Childhood Adrenocortical Carcinoma

200672 citationsJournal Article

Authors

Patrícia Zancanella · Universidade Federal do Paraná

Mara Albonei Dudeque Pianovski · Gaertner (United States)

Brás Heleno de Oliveira · Universidade Federal do Paraná

Sima Ferman · Instituto Nacional do Câncer

Gislaine Custodio Custodio Piovezan · Universidade Federal do Paraná

Leniza L. Lichtvan · Universidade Federal do Paraná

Suely Z. Voss

Abstract

Mitotane daily dose to maintain TL is variable and monitoring should start 1.5 months after the beginning of treatment. CED combined with mitotane is the best available pharmacologic treatment for ACC, but further studies are required to characterize different profiles of therapeutic response.

Topics & Keywords

Adrenal and Paraganglionic Tumors Glioma Diagnosis and Treatment Cancer, Hypoxia, and Metabolism

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Pediatric Hematology/Oncology

Volume 28, Issue 8, pp. 513-524

DOI: 10.1097/01.mph.0000212965.52759.1c

Field-Weighted Citation Impact: 1.76